ACRV
Acrivon Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.09 / 10
Netural
Analyst sentiment is overwhelmingly bullish with a 100% Buy rating from one report, yet the broader analyst coverage is limited. Fund-flow analysis shows a good score of 7.42/10, though individual flow trends (overall, block, small, medium, large, extra-large) are negative, hinting at liquidity inflows but downward price pressure.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionPiper Sandler
Times predicted1
Historical Win Rate100.0%
What is the market sentiment for ACRV?
- ACRV holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.09/10 (Netural).
